This website uses cookies. For more information please contact us or consult our privacy policy.

Your binder contains too many pages, the maximum is 40.

We are unable to add this page to your binder, please try again later.

This page has been added to your binder.

Matthew O'Connor
Matthew J. O'Connor
Partner
Washington +1 202 662 5469 moconnor@cov.com Download V-card

Matthew O'Connor is co-chair of the Life Sciences Litigation and Investigations Practice Group and is resident in the firm’s Washington Office.

Mr. O'Connor has extensive experience in all aspects of the white collar defense practice, with a particular emphasis representing life sciences companies and executives in broad-ranging federal and state civil and criminal investigations, follow-on consumer protection actions, and congressional investigations. He also has extensive experience in defending False Claims Act litigation and follow-on litigation arising from governmental investigations.

Life Sciences Investigations and Litigation

  • Represent numerous pharmaceutical and biotechnology companies in ongoing criminal and civil investigations concerning sales and marketing practices, government price reporting, and good manufacturing practices.
  • Represent several pharmaceutical and biotechnology companies in federal and state false claims act litigation concerning sales and marketing practices and FDA post-marketing reporting.
  • Represented GlaxoSmithKline in federal criminal and civil investigations and 2012 global resolution of three investigations concerning sales, marketing, pricing, and FDA reporting practices involving the company’s major products.
  • Represented Alpharma, Inc. in federal investigation and 2010 civil resolution concerning alleged violations of the Anti-Kickback Statute.
  • Represented GlaxoSmithKline in federal criminal and civil investigation and 2010 resolution concerning manufacturing practices at the company’s former manufacturing facility in Puerto Rico. Represented company in related consumer protection investigation and settlement with 37 states.
  • Represented Merck in investigation and 2008 civil resolution with United States and 49 states related to price reporting and sales and marketing practices.
  • Represented Biovail Pharmaceuticals, Inc. in investigation and 2008 resolution concerning violations of the Anti-Kickback Statute.
  • Represented pharmaceutical companies in investigation and 2007 resolution, including deferred prosecution agreement, concerning sales and marketing practices.
  • Obtained criminal and civil declination in federal investigation of pharmaceutical company concerning FDA reporting requirements.
  • Obtained criminal and civil declination in federal investigation of biotechnology company concerning sales and marketing practices.
  • Obtained criminal declination in federal investigation of device company concerning marketing practices.

Congressional Investigations 

  • Represented pharmaceutical company in Senate Special Committee on Aging investigation concerning product price levels.
  • Represented device company in Senate Finance Committee investigation concerning consultant payments.
  • Represented device and pharmaceutical companies in Senate Special Committee on Aging investigations concerning sponsorship of independent medical education programs.

Other Investigations 

  • Represented client in investigation by the Special Inspector General for the Troubled Asset Relief Program (SIG TARP) concerning potential mortgage work-out services fraud.
  • Represented financial institution in federal investigation concerning lending practices.
  • Represented building products manufacturer in internal investigation related to alleged accounting irregularities.
  • Legal 500 US, Healthcare: Life Sciences (2013, 2016)
  • Legal 500 US, M&A: Commercial Deals and Contracts (2016)
  • Legal 500 US, Litigation: White Collar Criminal Defense (2012)